Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.54 |
| ▸ | JAK1 | P23458 | 9/20 | 0.54 |
| ▸ | TYK2 | P29597 | 9/20 | 0.54 |
| ▸ | JAK3 | P52333 | 9/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800324 | 0.94 | JAK2 (0.63) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2802325 | 0.88 | JAK2 (0.60) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL2826310 | 0.87 | JAK2 (0.66) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL2800224 | 0.85 | JAK1 (0.68) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2798728 | 0.84 | JAK2 (0.70) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL2795573 | 0.83 | JAK2 (0.63) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL2800853 | 0.82 | JAK2 (0.65) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL2797785 | 0.81 | JAK2 (0.51) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2800367 | 0.80 | JAK2 (0.60) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2798850 | 0.80 | JAK2 (0.71) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | claimed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.